CoChat

The failure of torcetrapib: what have we learned?

Open access
Joy, T R, Hegele, R A · 2008 · British Journal of Pharmacology
Cited by 44

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The failure of the cholesterol ester transfer protein (CETP) inhibitor, torcetrapib, has led to questions regarding whether the molecule itself or the mechanism of CETP inhibition was responsible for the adverse cardiovascular outcomes. Given the association with increases in blood pressure and plasma aldosterone levels, torcetrapib has been postulated to have adverse ‘off‐target’ effects. In this issue of British Journal of Pharmacology, Forrest and co‐workers have elegantly investigated these effects, demonstrating two salient points—(1) the pressor effect of torcetrapib is independent of CETP inhibition and (2) although associated with hyperaldosteronism, the pressor effect is likely not mediated by hyperaldosteronism. Anacetrapib, by contrast, did not demonstrate any pressor or off‐target effects. Despite these findings, it remains to be proven whether the adverse cardiovascular outcomes from torcetrapib were indeed related to the pressor effects and whether CETP inhibition by other agents will result in beneficial clinical outcomes. Yet, the studies of Forrest and co‐workers do bring us closer to unravelling the reasons behind the failure of torcetrapib. British Journal of Pharmacology (2008) 154, 1379–1381; doi:fn1; published online 9 June 2008

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjp.2008.248

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Effects of torcetrapib in patients at high risk for coronary events

    Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 4×

    “…of ILLUMINATE revealed increased aldosterone levels in the torcetrapib arm, although a direct comparison of the mean values was not possible due to only 87–88% of samples being analysed and 53–57% of samples having aldosterone levels below the lower limit of quantification (Barter et al., 2007).”
    BackgroundResultInfluential

Show all 1 references

Cited by

See all 44

Metadata

Authors
Joy, T. R., & Hegele, R. A.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-08
Volume
154
Issue
7
Pages
1379-1381
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2085083234
Cited by
44
References
1
FWCI
3.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The failure of torcetrapib: what have we learned? https://app.cochat.ai/papers/10.1038/bjp.2008.248
The paper
Joy, T. R., & Hegele, R. A. (2008). The failure of torcetrapib: what have we learned? British Journal of Pharmacology. https://doi.org/10.1038/bjp.2008.248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.